GlassScriptPhysician profile
Heather Calmes Bylander
NPI 1174384531
$2,974.42
in general payments reported to CMS, 2019-2025
22 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 89% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,811 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,974.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $600.87 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $316.75 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $309.13 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Ironshore Pharmaceuticals INC. | $252.07 | 2024 | |
| Amgen INC. | $239.65 | 2024-2025 | Evenity, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $237.01 | 2024-2025 | |
| Abbvie INC. | $223.31 | 2024-2025 | |
| Pfizer INC. | $177.58 | 2024-2025 | |
| Gilead Sciences, INC. | $116.15 | 2025 | Yeztugo |
| Exact Sciences Corporation | $96.10 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Shield Therapeutics INC | $95.42 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.62 | 2024 | Jardiance |
| Sumitomo Pharma America, INC. | $44.28 | 2024 | Gemtesa |
| Collegium Pharmaceutical, INC. | $38.71 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $34.06 | 2025 | Trelegy Ellipta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $30.85 | 2024 | Quviviq |
| Medtronic, INC. | $25.42 | 2025 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $22.16 | 2025 | Spravato |
| Astellas Pharma US INC | $18.60 | 2025 | Veozah |
| Tms Neurohealth Centers INC. | $17.15 | 2025 | Tms Neurohealth Centers INC. |
| Takeda Pharmaceuticals U.S.A., INC. | $14.71 | 2025 | Trintellix |
| Nevro Corp. | $13.82 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Bylander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.